You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRamipril
Accession NumberDB00178  (APRD00009)
TypeSmall Molecule
GroupsApproved
Description

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

Structure
Thumb
Synonyms
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Altace (tn)
Ramipril
Ramiprilum
Tritace
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-ramiprilcapsule5 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilcapsule2.5 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilcapsule1.25 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilcapsule15 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-ramiprilcapsule10 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Act Ramiprilcapsule5 mgoralActavis Pharma Company2007-10-02Not applicableCanada
Act Ramiprilcapsule2.5 mgoralActavis Pharma Company2007-10-02Not applicableCanada
Act Ramiprilcapsule1.25 mgoralActavis Pharma Company2007-10-02Not applicableCanada
Act Ramiprilcapsule10 mgoralActavis Pharma Company2007-10-02Not applicableCanada
Altacecapsule10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-05-24Not applicableUs
Altacetablet10 mgoralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Altacecapsule10 mg/1oralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
Altacecapsule10 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-03-24Not applicableCanada
Altacetablet5 mgoralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Altacecapsule5 mg/1oralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
Altacecapsule1.25 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-28Not applicableCanada
Altacetablet1.25 mgoralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Altacecapsule2.5 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-04-21Not applicableCanada
Altacecapsule2.5 mg/1oralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
Altacecapsule5 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-04-21Not applicableCanada
Altacetablet2.5 mgoralValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Altacecapsule15.0 mgoralValeant Canada Lp Valeant Canada S.E.C.2006-08-14Not applicableCanada
Altacecapsule1.25 mg/1oralPfizer Laboratories Div Pfizer Inc1991-01-28Not applicableUs
Altace Cap 1.25mgcapsule1.25 mgoralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Altace Cap 10mgcapsule10 mgoralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Altace Cap 2.5mgcapsule2.5 mgoralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Altace Cap 5mgcapsule5 mgoralHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Auro-ramiprilcapsule2.5 mgoralAuro Pharma Inc2012-09-13Not applicableCanada
Auro-ramiprilcapsule10 mgoralAuro Pharma Inc2012-09-13Not applicableCanada
Auro-ramiprilcapsule1.25 mgoralAuro Pharma Inc2012-09-13Not applicableCanada
Auro-ramiprilcapsule5 mgoralAuro Pharma Inc2012-09-13Not applicableCanada
Ava-ramipriltablet2.5 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-ramipriltablet1.25 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-ramipriltablet10 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-ramipriltablet5 mgoralAvanstra Inc2011-09-192014-08-21Canada
Bio-ramiprilcapsule10 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-ramiprilcapsule5 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-ramiprilcapsule2.5 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-ramiprilcapsule1.25 mgoralDominion Pharmacal2010-06-01Not applicableCanada
Dom-ramiprilcapsule10 mgoralDominion Pharmacal2010-06-01Not applicableCanada
Dom-ramiprilcapsule5 mgoralDominion Pharmacal2010-06-01Not applicableCanada
Dom-ramiprilcapsule2.5 mgoralDominion Pharmacal2010-06-01Not applicableCanada
Ipg-ramiprilcapsule15 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilcapsule10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilcapsule5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilcapsule2.5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ramiprilcapsule1.25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-ramiprilcapsule2.5 mgoralJamp Pharma Corporation2010-03-10Not applicableCanada
Jamp-ramiprilcapsule10 mgoralJamp Pharma Corporation2010-03-10Not applicableCanada
Jamp-ramiprilcapsule15 mgoralJamp Pharma Corporation2015-09-08Not applicableCanada
Jamp-ramiprilcapsule1.25 mgoralJamp Pharma Corporation2010-03-10Not applicableCanada
Jamp-ramiprilcapsule5 mgoralJamp Pharma Corporation2010-03-10Not applicableCanada
Mar-ramiprilcapsule1.25 mgoralMarcan Pharmaceuticals Inc2015-06-17Not applicableCanada
Mar-ramiprilcapsule15.0 mgoralMarcan Pharmaceuticals Inc2014-09-10Not applicableCanada
Mar-ramiprilcapsule10.0 mgoralMarcan Pharmaceuticals Inc2015-01-09Not applicableCanada
Mar-ramiprilcapsule5.0 mgoralMarcan Pharmaceuticals Inc2015-01-09Not applicableCanada
Mar-ramiprilcapsule2.5 mgoralMarcan Pharmaceuticals Inc2015-01-09Not applicableCanada
Mint-ramiprilcapsule5.0 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-ramiprilcapsule15.0 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-ramiprilcapsule2.5 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-ramiprilcapsule1.25 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-ramiprilcapsule10.0 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mylan-ramiprilcapsule10 mgoralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
Mylan-ramiprilcapsule5.0 mgoralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
Mylan-ramiprilcapsule2.5 mgoralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
Mylan-ramiprilcapsule1.25 mgoralMylan Pharmaceuticals Ulc2008-07-02Not applicableCanada
PMS-ramiprilcapsule15 mgoralPharmascience Inc2010-05-11Not applicableCanada
PMS-ramiprilcapsule5 mgoralPharmascience Inc2009-10-06Not applicableCanada
PMS-ramiprilcapsule2.5 mgoralPharmascience Inc2009-10-06Not applicableCanada
PMS-ramiprilcapsule1.25 mgoralPharmascience Inc2009-10-06Not applicableCanada
PMS-ramiprilcapsule10 mgoralPharmascience Inc2009-10-06Not applicableCanada
Priva-ramiprilcapsule5 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-ramiprilcapsule2.5 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-ramiprilcapsule10 mgoralPharmapar IncNot applicableNot applicableCanada
Pro-ramipril - 1.25capsule1.25 mgoralPro Doc Limitee2011-11-25Not applicableCanada
Pro-ramipril - 10capsule10 mgoralPro Doc Limitee2011-11-25Not applicableCanada
Pro-ramipril - 2.5capsule2.5 mgoralPro Doc Limitee2011-11-25Not applicableCanada
Pro-ramipril - 5capsule5 mgoralPro Doc Limitee2011-11-25Not applicableCanada
Ramacetablet2.5 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ramacetablet10 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ramacetablet1.25 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ramacetablet5 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ramiprilcapsule10 mgoralLaboratoire Riva Inc2008-03-14Not applicableCanada
Ramiprilcapsule1.25 mgoralLaboratoire Riva Inc2008-03-17Not applicableCanada
Ramiprilcapsule2.5 mgoralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
Ramiprilcapsule2.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Ramiprilcapsule5 mgoralSanis Health Inc2011-11-24Not applicableCanada
Ramiprilcapsule5 mgoralLaboratoire Riva Inc2008-03-14Not applicableCanada
Ramiprilcapsule1.25 mgoralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
Ramiprilcapsule1.25 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Ramiprilcapsule2.5 mgoralSanis Health Inc2011-11-24Not applicableCanada
Ramiprilcapsule2.5 mgoralLaboratoire Riva Inc2008-03-14Not applicableCanada
Ramiprilcapsule10 mgoralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
Ramiprilcapsule10 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Ramiprilcapsule5 mgoralSivem Pharmaceuticals Ulc2010-03-01Not applicableCanada
Ramiprilcapsule5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Ramiprilcapsule10 mgoralSanis Health Inc2011-11-24Not applicableCanada
Ramipril Capsulescapsule10.0 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril Capsulescapsule5.0 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril Capsulescapsule2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril Capsulescapsule1.25 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ramipril-10capsule10 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ramipril-2.5capsule2.5 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ramipril-5capsule5 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ran-ramiprilcapsule2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilcapsule1.25 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilcapsule10 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilcapsule5 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-06-25Not applicableCanada
Ran-ramiprilcapsule15 mgoralRanbaxy Pharmaceuticals Canada Inc.2014-11-24Not applicableCanada
Ratio-ramiprilcapsule1.25 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Ratio-ramiprilcapsule15 mgoralRatiopharm Inc Division Of Teva Canada Limited2009-05-052014-09-19Canada
Ratio-ramiprilcapsule10.0 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Ratio-ramiprilcapsule5.0 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Ratio-ramiprilcapsule2.5 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-12-132014-09-19Canada
Rbx-ramiprilcapsule10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-ramiprilcapsule5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-ramiprilcapsule2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Rbx-ramiprilcapsule1.25 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Sandoz Ramipriltablet1.25 mgoralSandoz Canada Incorporated2007-07-05Not applicableCanada
Sandoz Ramipriltablet10 mgoralSandoz Canada Incorporated2007-07-05Not applicableCanada
Sandoz Ramipriltablet5 mgoralSandoz Canada Incorporated2007-07-05Not applicableCanada
Sandoz Ramipriltablet2.5 mgoralSandoz Canada Incorporated2007-07-05Not applicableCanada
Teva-ramiprilcapsule15 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-ramiprilcapsule10 mgoralTeva Canada Limited2007-05-02Not applicableCanada
Teva-ramiprilcapsule1.25 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-ramiprilcapsule5 mgoralTeva Canada Limited2007-05-02Not applicableCanada
Teva-ramiprilcapsule2.5 mgoralTeva Canada Limited2007-05-02Not applicableCanada
Van-ramiprilcapsule10 mgoralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilcapsule5 mgoralVanc Pharmaceuticals Inc2016-02-12Not applicableCanada
Van-ramiprilcapsule2.5 mgoralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilcapsule1.25 mgoralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Van-ramiprilcapsule15 mgoralVanc Pharmaceuticals Inc2016-01-27Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ramiprilcapsule15 mgoralApotex Inc2009-05-01Not applicableCanada
Apo-ramiprilcapsule10 mgoralApotex Inc2006-12-12Not applicableCanada
Apo-ramiprilcapsule5 mgoralApotex Inc2006-12-12Not applicableCanada
Apo-ramiprilcapsule2.5 mgoralApotex Inc2006-12-12Not applicableCanada
Apo-ramiprilcapsule1.25 mgoralApotex Inc2006-12-12Not applicableCanada
Ramiprilcapsule2.5 mg/1oralAccord Healthcare Inc.2014-07-01Not applicableUs
Ramiprilcapsule10 mg/1oralMedsource Pharmaceuticals2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralCardinal Health2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralProficient Rx LP2008-06-10Not applicableUs
Ramiprilcapsule1.25 mg/1oralCarilion Materials Management2008-06-18Not applicableUs
Ramiprilcapsule, gelatin coated10 mg/1oralDIRECT RX2016-01-13Not applicableUs
Ramiprilcapsule10 mg/1oralAccord Healthcare Inc.2014-07-01Not applicableUs
Ramiprilcapsule5 mg/1oralUnit Dose Services2008-06-24Not applicableUs
Ramiprilcapsule2.5 mg/1oralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralbryant ranch prepack2008-06-18Not applicableUs
Ramiprilcapsule1.25 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
Ramiprilcapsule2.5 mg/1oralAmerican Health Packaging2008-01-22Not applicableUs
Ramiprilcapsule1.25 mg/1oralRoxane Laboratories, Inc2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralTeva Pharmaceuticals USA Inc2008-06-242016-03-31Us
Ramiprilcapsule5 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Ramiprilcapsule2.5 mg/1oralPhysicians Total Care, Inc.2008-02-13Not applicableUs
Ramiprilcapsule10 mg/1oralApotex Corp.2008-06-20Not applicableUs
Ramiprilcapsule2.5 mg/1oralAurobindo Pharma Limited2011-06-08Not applicableUs
Ramiprilcapsule5 mg/1oralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
Ramiprilcapsule5 mg/1oralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule1.25 mg/1oralAccord Healthcare Inc.2014-07-01Not applicableUs
Ramiprilcapsule2.5 mg/1oralPd Rx Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule2.5 mg/1oralCardinal Health2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralProficient Rx LP2008-06-10Not applicableUs
Ramiprilcapsule5 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule5 mg/1oralTeva Pharmaceuticals USA Inc2008-06-242016-03-31Us
Ramiprilcapsule2.5 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Ramiprilcapsule10 mg/1oralPhysicians Total Care, Inc.2008-02-21Not applicableUs
Ramiprilcapsule5 mg/1oralApotex Corp.2008-06-20Not applicableUs
Ramiprilcapsule1.25 mg/1oralAurobindo Pharma Limited2011-06-08Not applicableUs
Ramiprilcapsule2.5 mg/1oralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
Ramiprilcapsule2.5 mg/1oralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule10 mg/1oralActavis Pharma, Inc.2007-12-26Not applicableUs
Ramiprilcapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.2008-06-09Not applicableUs
Ramiprilcapsule10 mg/1oralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralProficient Rx LP2008-06-10Not applicableUs
Ramiprilcapsule2.5 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule2.5 mg/1oralTeva Pharmaceuticals USA Inc2008-06-24Not applicableUs
Ramiprilcapsule1.25 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Ramiprilcapsule5 mg/1oralPhysicians Total Care, Inc.2009-07-30Not applicableUs
Ramiprilcapsule2.5 mg/1oralApotex Corp.2008-06-20Not applicableUs
Ramiprilcapsule10 mg/1oralCadila Healthcare Limited2010-11-20Not applicableUs
Ramiprilcapsule1.25 mg/1oralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
Ramiprilcapsule1.25 mg/1oralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2008-06-24Not applicableUs
Ramiprilcapsule5 mg/1oralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralDIRECT RX2015-01-01Not applicableUs
Ramiprilcapsule10 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule5 mg/1oralActavis Pharma, Inc.2007-12-26Not applicableUs
Ramiprilcapsule10 mg/1oralRoxane Laboratories, Inc2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralRebel Distributors Corp2007-12-26Not applicableUs
Ramiprilcapsule10 mg/301oralNorthwind Pharmaceuticals2014-05-07Not applicableUs
Ramiprilcapsule1.25 mg/1oralApotex Corp.2008-06-20Not applicableUs
Ramiprilcapsule5 mg/1oralCadila Healthcare Limited2010-11-20Not applicableUs
Ramiprilcapsule10 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
Ramiprilcapsule1.25 mg/1oralAmerican Health Packaging2008-06-09Not applicableUs
Ramiprilcapsule10 mg/1oralAidarex Pharmaceuticals LLC2011-06-08Not applicableUs
Ramiprilcapsule2.5 mg/1oralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Ramiprilcapsule1.25 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule2.5 mg/1oralActavis Pharma, Inc.2007-12-26Not applicableUs
Ramiprilcapsule2.5 mg/1oralRebel Distributors Corp2007-12-26Not applicableUs
Ramipriltablet5 mg/1oralNorthwind Pharmaceuticals2014-12-30Not applicableUs
Ramiprilcapsule10 mg/1oralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralCadila Healthcare Limited2010-11-20Not applicableUs
Ramiprilcapsule5 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
Ramiprilcapsule10 mg/1oralAmerican Health Packaging2008-01-22Not applicableUs
Ramiprilcapsule5 mg/1oralRoxane Laboratories, Inc2008-06-18Not applicableUs
Ramiprilcapsule5 mg/1oralAidarex Pharmaceuticals LLC2011-06-08Not applicableUs
Ramiprilcapsule1.25 mg/1oralDr. Reddy's Laboratories Limited2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule10 mg/1oralAurobindo Pharma Limited2011-06-08Not applicableUs
Ramiprilcapsule5 mg/1oralProficient Rx LP2007-12-26Not applicableUs
Ramiprilcapsule1.25 mg/1oralActavis Pharma, Inc.2007-12-26Not applicableUs
Ramiprilcapsule5 mg/1oralAccord Healthcare Inc.2014-07-01Not applicableUs
Ramiprilcapsule10 mg/1oralREMEDYREPACK INC.2011-08-22Not applicableUs
Ramiprilcapsule1.25 mg/1oralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralbryant ranch prepack2009-05-05Not applicableUs
Ramiprilcapsule10 mg/1oralDispensing Solutions, Inc.2008-06-18Not applicableUs
Ramiprilcapsule2.5 mg/1oralProficient Rx LP2015-02-12Not applicableUs
Ramiprilcapsule5 mg/1oralAtlantic Biologicals Corps2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralUnit Dose Services2008-06-242016-03-31Us
Ramiprilcapsule5 mg/1oralGolden State Medical Supply, Inc.2008-06-18Not applicableUs
Ramiprilcapsule1.25 mg/1oralCadila Healthcare Limited2010-11-20Not applicableUs
Ramiprilcapsule2.5 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-11-20Not applicableUs
Ramiprilcapsule5 mg/1oralAmerican Health Packaging2008-01-22Not applicableUs
Ramiprilcapsule2.5 mg/1oralRoxane Laboratories, Inc2008-06-18Not applicableUs
Ramiprilcapsule10 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Ramiprilcapsule1.25 mg/1oralPhysicians Total Care, Inc.2008-07-14Not applicableUs
Ramiprilcapsule5 mg/1oralBlue Point Laboratories2014-01-01Not applicableUs
Ramiprilcapsule5 mg/1oralAurobindo Pharma Limited2011-06-08Not applicableUs
Ramiprilcapsule10 mg/1oralExelan Pharmaceuticals, Inc.2008-06-27Not applicableUs
Ramiprilcapsule10 mg/1oralLupin Pharmaceuticals, Inc.2008-06-10Not applicableUs
Ramiprilcapsule10 mg/1oralBlenheim Pharmacal, Inc.2014-01-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcovilSanofi-Aventis (Spain)
CaraselAlmirall (Spain)
CardaceSanofi-Aventis (Finland), Aventis (India), Aventis (Indonesia)
DelixAventis (Germany, Turkey),
HyprenAstraZeneca (Austria)
LostapresTemis (Argentina)
PramaceAstra (Ireland), AstraZeneca (Sweden)
QuarkPolifarma (Italy)
TriatecSanofi-Aventis (Brazil, Chili, Denmark, France, Greece, Indonesia, Italy,Norway, Portugal, Sweden, Switzerland)
TritaceSanofi-Aventis (Argentina, Australia, Austria, Belgium, Czech Republic, Hong Kong, Hungary, Ireland, Israel, Malaysia, Mexico, Netherlands, Poland, Singapor, Thailand, United Kingdom), Aventis (New Zealand, Philippines, South Africa)
VesdilAstraZeneca (Germany), Promed (Germany)
Brand mixtures
NameLabellerIngredients
Altace HctValeant Canada Lp Valeant Canada S.E.C.
Altace Plus Felodipine 2.5mg + 2.5mgSanofi Aventis Canada Inc
Altace Plus Felodipine 5mg + 5mgSanofi Aventis Canada Inc
Apo-ramipril/hctzApotex Inc
PMS-ramipril-hctzPharmascience Inc
Ramipril-hctzSanis Health Inc
Ran-ramipril HctzRanbaxy Pharmaceuticals Canada Inc.
Teva-ramipril/hctzTeva Canada Limited
SaltsNot Available
Categories
UNIIL35JN3I7SJ
CAS number87333-19-5
WeightAverage: 416.5106
Monoisotopic: 416.231122144
Chemical FormulaC23H32N2O5
InChI KeyInChIKey=HDACQVRGBOVJII-JBDAPHQKSA-N
InChI
InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
IUPAC Name
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid
SMILES
[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[[email protected]](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Cyclic alcohol
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.
PharmacodynamicsRamipril is an ACE inhibitor similar to benazepril, fosinopril and quinapril. It is an inactive prodrug that is converted to ramiprilat in the liver, the main site of activation, and kidneys. Ramiprilat confers blood pressure lowing effects by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of ramiprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Ramiprilat, the principle active metabolite of ramipril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Ramipril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
Related Articles
AbsorptionThe extent of absorption is at least 50-60%. Food decreases the rate of absorption from the GI tract without affecting the extent of absorption. The absolute bioavailabilities of ramipril and ramiprilat were 28% and 44%, respectively, when oral administration was compared to intravenous administration.
Volume of distributionNot Available
Protein bindingProtein binding of ramipril is about 73% and that of ramiprilat about 56%.
Metabolism

Hepatic metabolism accounts for 75% of total ramipril metabolism. 25% of hepatic metabolism produces the active metabolite ramiprilat via liver esterase enzymes. 100% of renal metabolism converts ramipril to ramiprilat. Other metabolites, diketopiperazine ester, the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat, are inactive.

SubstrateEnzymesProduct
Ramipril
Not Available
Diketopiperazine acidDetails
Ramipril
Not Available
Diketopiperazine esterDetails
Ramipril
RamiprilatDetails
Route of eliminationNot Available
Half lifePlasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.
ClearanceNot Available
ToxicitySymptoms of overdose may include excessive peripheral vasodilation (with marked hypotension and shock), bradycardia, electrolyte disturbances, and renal failure. The most likely adverse reactions are symptoms attributable to its blood-pressure lowing effect. May cause headache, dizziness, asthenia, chest pain, nausea, peripheral edema, somnolence, impotence, rash, arthritis, and dyspnea. LD50 = 10933 mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ramipril Action PathwayDrug actionSMP00154
Ramipril Metabolism PathwayDrug metabolismSMP00597
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs4344 Not AvailableA Allele, homozygoteMore rapid response to drug treatment17885551
Angiotensin-converting enzyme
Gene symbol: ACE
UniProt: P12821
rs4344 Not AvailableG Allele, homozygoteMore rapid response to drug treatment17885551
Angiotensin-converting enzyme 2
Gene symbol: ACE2
UniProt: Q9BYF1
rs4344 Not AvailableG > AThose with the AA or GG gentypes respond better to treatment17885551
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9159
Blood Brain Barrier-0.8726
Caco-2 permeable-0.8491
P-glycoprotein substrateSubstrate0.7263
P-glycoprotein inhibitor INon-inhibitor0.7002
P-glycoprotein inhibitor IIInhibitor0.6295
Renal organic cation transporterNon-inhibitor0.8869
CYP450 2C9 substrateNon-substrate0.8541
CYP450 2D6 substrateNon-substrate0.8969
CYP450 3A4 substrateNon-substrate0.5082
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9304
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5691
Ames testNon AMES toxic0.9108
CarcinogenicityNon-carcinogens0.9267
BiodegradationNot ready biodegradable0.8903
Rat acute toxicity1.6732 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.98
hERG inhibition (predictor II)Non-inhibitor0.7901
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals inc
  • Actavis elizabeth llc
  • Apotex inc
  • Cipla ltd
  • Dr reddys laboratories ltd
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • King Pharmaceuticals, Inc.
Packagers
Dosage forms
FormRouteStrength
Capsuleoral15.0 mg
Tabletoral
Capsuleoral1.25 mg
Capsuleoral15 mg
Capsuleoral10.0 mg
Capsuleoral5.0 mg
Capsuleoral10 mg
Capsuleoral2.5 mg
Capsuleoral5 mg
Capsuleoral1.25 mg/1
Capsuleoral10 mg/1
Capsuleoral10 mg/301
Capsuleoral2.5 mg/1
Capsuleoral5 mg/1
Capsule, gelatin coatedoral10 mg/1
Tabletoral5 mg/1
Tabletoral1.25 mg
Tabletoral10 mg
Tabletoral2.5 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Altace 10 mg capsule2.87USD capsule
Altace 2.5 mg capsule2.54USD capsule
Altace 5 mg capsule2.53USD capsule
Altace 10 mg tablet2.37USD tablet
Altace 1.25 mg capsule2.2USD capsule
Ramipril 10 mg capsule2.19USD capsule
Altace 5 mg tablet2.02USD tablet
Altace 2.5 mg tablet1.93USD tablet
Ramipril 5 mg capsule1.87USD capsule
Ramipril 2.5 mg capsule1.78USD capsule
Altace 1.25 mg tablet1.63USD tablet
Ramipril 1.25 mg capsule1.59USD capsule
Altace 10 mg Tablet1.14USD tablet
Altace 2.5 mg Tablet0.9USD tablet
Altace 5 mg Tablet0.9USD tablet
Altace 1.25 mg Tablet0.78USD tablet
Apo-Ramipril 10 mg Tablet0.64USD tablet
Co Ramipril 10 mg Tablet0.64USD tablet
Jamp-Ramipril 10 mg Tablet0.64USD tablet
Mylan-Ramipril 10 mg Tablet0.64USD tablet
Novo-Ramipril 10 mg Tablet0.64USD tablet
Pms-Ramipril 10 mg Tablet0.64USD tablet
Ramipril 10 mg Tablet0.64USD tablet
Ran-Ramipril 10 mg Tablet0.64USD tablet
Ratio-Ramipril 10 mg Tablet0.64USD tablet
Sandoz Ramipril 10 mg Tablet0.64USD tablet
Apo-Ramipril 2.5 mg Tablet0.5USD tablet
Apo-Ramipril 5 mg Tablet0.5USD tablet
Co Ramipril 2.5 mg Tablet0.5USD tablet
Co Ramipril 5 mg Tablet0.5USD tablet
Jamp-Ramipril 2.5 mg Tablet0.5USD tablet
Jamp-Ramipril 5 mg Tablet0.5USD tablet
Mylan-Ramipril 2.5 mg Tablet0.5USD tablet
Mylan-Ramipril 5 mg Tablet0.5USD tablet
Novo-Ramipril 2.5 mg Tablet0.5USD tablet
Novo-Ramipril 5 mg Tablet0.5USD tablet
Pms-Ramipril 2.5 mg Tablet0.5USD tablet
Pms-Ramipril 5 mg Tablet0.5USD tablet
Ramipril 2.5 mg Tablet0.5USD tablet
Ramipril 5 mg Tablet0.5USD tablet
Ran-Ramipril 2.5 mg Tablet0.5USD tablet
Ran-Ramipril 5 mg Tablet0.5USD tablet
Ratio-Ramipril 2.5 mg Tablet0.5USD tablet
Ratio-Ramipril 5 mg Tablet0.5USD tablet
Sandoz Ramipril 2.5 mg Tablet0.5USD tablet
Sandoz Ramipril 5 mg Tablet0.5USD tablet
Apo-Ramipril 1.25 mg Tablet0.44USD tablet
Co Ramipril 1.25 mg Tablet0.44USD tablet
Jamp-Ramipril 1.25 mg Tablet0.44USD tablet
Mylan-Ramipril 1.25 mg Tablet0.44USD tablet
Pms-Ramipril 1.25 mg Tablet0.44USD tablet
Ramipril 1.25 mg Tablet0.44USD tablet
Ran-Ramipril 1.25 mg Tablet0.44USD tablet
Ratio-Ramipril 1.25 mg Tablet0.44USD tablet
Sandoz Ramipril 1.25 mg Tablet0.44USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1338344 No1996-05-212013-05-21Canada
CA2382387 No2005-06-212020-08-25Canada
US5403856 No1995-04-042012-04-04Us
US7368469 No2000-08-302020-08-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point109 °CPhysProp
water solubility3.5mg/LNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.039 mg/mLALOGPS
logP0.92ALOGPS
logP1.47ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.75ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity111.19 m3·mol-1ChemAxon
Polarizability44.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Edward Wilson, Martin Beasley, “Stabilized ramipril compositions and methods of making.” U.S. Patent US20060134213, issued June 22, 2006.

US20060134213
General References
  1. Cacciapuoti F, Capasso A, Mirra G, De Nicola A, Minicucci F, Gentile S: Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine. Int J Cardiol. 1998 Jan 31;63(2):175-8. [PubMed:9510492 ]
  2. Kleinert S: HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation. Lancet. 1999 Sep 4;354(9181):841. [PubMed:10485736 ]
External Links
ATC CodesC09AA05C10BX04C10BX06C09BA05C09BB07C09BB05
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelNot Available
MSDSDownload (53.6 KB)
Interactions
Drug Interactions
Drug
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Ramipril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Ramipril.
AliskirenAliskiren may increase the hyperkalemic activities of Ramipril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Ramipril.
AmifostineRamipril may increase the hypotensive activities of Amifostine.
AprotininAprotinin may decrease the antihypertensive activities of Ramipril.
ArdeparinArdeparin may increase the hyperkalemic activities of Ramipril.
AzathioprineRamipril may increase the myelosuppressive activities of Azathioprine.
BrimonidineBrimonidine may increase the antihypertensive activities of Ramipril.
ButabarbitalButabarbital may increase the hypotensive activities of Ramipril.
ButethalButethal may increase the hypotensive activities of Ramipril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Ramipril.
CiprofloxacinRamipril may increase the arrhythmogenic activities of Ciprofloxacin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Ramipril.
DiazoxideDiazoxide may increase the hypotensive activities of Ramipril.
DrospirenoneRamipril may increase the hyperkalemic activities of Drospirenone.
DuloxetineRamipril may increase the orthostatic hypotensive activities of Duloxetine.
EplerenoneEplerenone may increase the hyperkalemic activities of Ramipril.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Ramipril.
HeparinHeparin may increase the hyperkalemic activities of Ramipril.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Ramipril.
HexobarbitalHexobarbital may increase the hypotensive activities of Ramipril.
IcatibantIcatibant may decrease the antihypertensive activities of Ramipril.
InfliximabThe risk or severity of adverse effects can be increased when Ramipril is combined with Infliximab.
IronThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron Dextran.
LevodopaRamipril may increase the orthostatic hypotensive activities of Levodopa.
LithiumThe serum concentration of Lithium can be increased when it is combined with Ramipril.
MethohexitalMethohexital may increase the hypotensive activities of Ramipril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Ramipril.
MolsidomineMolsidomine may increase the hypotensive activities of Ramipril.
MoxonidineMoxonidine may increase the hypotensive activities of Ramipril.
NicorandilNicorandil may increase the hypotensive activities of Ramipril.
ObinutuzumabRamipril may increase the hypotensive activities of Obinutuzumab.
PentobarbitalPentobarbital may increase the hypotensive activities of Ramipril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Ramipril.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Ramipril.
PregabalinThe risk or severity of adverse effects can be increased when Ramipril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Ramipril.
QuinineQuinine may increase the hypotensive activities of Ramipril.
RisperidoneRamipril may increase the hypotensive activities of Risperidone.
RituximabRamipril may increase the hypotensive activities of Rituximab.
SacubitrilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sacubitril.
SecobarbitalSecobarbital may increase the hypotensive activities of Ramipril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Ramipril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Ramipril.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Ramipril is combined with Sodium aurothiomalate.
TadalafilTadalafil may increase the antihypertensive activities of Ramipril.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ramipril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Ramipril.
TizanidineTizanidine may increase the hypotensive activities of Ramipril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Ramipril.
TorasemideTorasemide may increase the hypotensive activities of Ramipril.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Ramipril.
TreprostinilTreprostinil may increase the hypotensive activities of Ramipril.
TriamtereneTriamterene may increase the hyperkalemic activities of Ramipril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Ramipril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Ramipril.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Ramipril.
VardenafilVardenafil may increase the antihypertensive activities of Ramipril.
YohimbineYohimbine may decrease the antihypertensive activities of Ramipril.
Food Interactions
  • Alcohol may increase the vasodilatory effects of ramipril.
  • Herbs that may attenuate the antihypertensive effect of ramipril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of ramipril.
  • Ramipril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Levitt DG, Schoemaker RC: Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat. BMC Clin Pharmacol. 2006 Jan 6;6:1. [PubMed:16398929 ]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Shah GB, Sharma S, Mehta AA, Goyal RK: Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000 Aug;36(2):169-75. [PubMed:10942157 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 24, 2016 01:51